A demonstration of SAMCell’s interface throughout the various stages of use: (a) landing page for image upload, (b) image selection and processing status, (c) visualization of segm... by Alexandra Dunnum VandeLoo (22209218)

Subjects:

Example images from the (a) Cytoplasm dataset and (b) LIVECell dataset used for training and example images from each of our evaluation datasets, (c) PBL-HEK and (d) PBL-N2a. by Alexandra Dunnum VandeLoo (22209218)

Subjects:

Fig 3 - by Yeong Chan Lee (8809223)

The HMR C-terminus is required for HMR localization in proximity to centromeres and HP1a-bound chromatin. by Andrea Lukacs (3752956)

Kaplan-Meier curves for time to DILI from treatment initiation, stratified by DM status (n = 152). by Ivanice D. Freire (15999195)

The HMR C-terminus is required for HMR physiological function in <i>D</i>. <i>melanogaster</i>. by Andrea Lukacs (3752956)

HbA1c by BMI for new and previous diabetes diagnoses at start of TB treatment. by Sharon E. Cox (7243847)

Subjects:

Differential expression analysis of nuclear transcripts after siAPOBEC3A depletion reveals induction of TP53 targets and decreases in cell cycle and cell growth regulator transcrip... by Mason A. McCool (11889842)

(a) A single Phase Contrast image of HEK cells from our PBL-HEK dataset, (b) annotated manually by an expert, (c) automatically annotated by Meta’s SAM-huge model, and (d) automati... by Alexandra Dunnum VandeLoo (22209218)

Subjects:

Estimated type III functional response of <i>Anagyrus cachamai</i> females at different ages (days) of their average lifespan (1–6 days) considering limited egg production. by María Aguirre (18127551)

The rate the bias decreases with sample duration is higher for cells with higher activity levels. by Liron Sheintuch (12078310)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)